Related references
Note: Only part of the references are listed.The high comorbidity burden of the hepatitis C virus infected population in the United States
Karly S. Louie et al.
BMC INFECTIOUS DISEASES (2012)
Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics
Micaela B. Reddy et al.
CLINICAL PHARMACOKINETICS (2012)
Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible
Micaela B. Reddy et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2011)
Genotype Differences in Susceptibility and Resistance Development of Hepatitis C Virus to Protease Inhibitors Telaprevir (VX-950) and Danoprevir (ITMN-191)
Ingrid Imhof et al.
HEPATOLOGY (2011)
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients
Edward J. Gane et al.
JOURNAL OF HEPATOLOGY (2011)
Hepatitis C virus resistance to protease inhibitors
Philippe Halfon et al.
JOURNAL OF HEPATOLOGY (2011)
Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior
Ravi Rajagopalan et al.
BIOCHEMISTRY (2009)
Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)
Scott D. Seiwert et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir
Cheri E. Klein et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects
J Ng et al.
Journal of the International AIDS Society (2008)
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers
A. D. Luber et al.
HIV MEDICINE (2007)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers
Alan Winston et al.
AIDS (2006)
Pharmacokinetic drug interaction profiles of proton pump inhibitors
Henning Blume et al.
DRUG SAFETY (2006)
Co-administration of atazanavir with proton-pump inhibitors and H2 blockers
L Khanlou et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals
MN Martinez et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Proton pump inhibitors and their drug interactions: an evidence-based approach
LB Gerson et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2001)
Share Paper
